Hughe Luckey News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article
Share this article
SHANGHAI, April 8, 2021 /PRNewswire/ Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to novel target discovery and development of novel therapeutics, today announced the appointment of Dr. Eric Rowinsky, President and Executive Chairman of the Board of Rgenix, Inc., and Dr. Manuel Hidalgo, Chief of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, to its Scientific Advisory Board. Drs. Rowinsky and Hidalgo will bring their strong expertise in translational and clinical development to support Genechem s mission to bring its innovative pipeline to global markets through novel target discovery, early development in China, and global partnership. ....

United States , San Antonio , University Of Texas , Eric Rowinsky , Manuel Hidalgo , Hughe Luckey , Yueqiong Cao , Johns Hopkins University , Head Of Research , Beth Israel Deaconess Medical Center , Presbyterian Weill Cornell Medical Center , Clearpath Development Co , Institute Of Drug Development , University Autonoma , Early Drug Development , Purple Biotech Ltd , Johns Hopkins School Of Medicine , Prnewswire Shanghai Genechem Co Ltd , Clinical Research , Gastrointestinal Oncology Program , Stemline Therapeutics Inc , Translational Research , Division Of Hematology , Kimmel Comprehensive Cancer Center At Johns Hopkins , Clinical Research Program , Good Research Practice ,